GPT and coronary artery disorder: Both treatments significantly lowered HOMA-IR; however, the decrease was similar between the groups (P = 0.724).<h4>Conclusions</h4>Pemafibrate is more effective than bezafibrate at reducing ALT levels while offering similar beneficial effects on insulin resistance and endothelial function in CAD patients with MASLD.